Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anixa BiosciencesANIX +0.36%31 3-Year EPS without NRI Growth Rate is 8.90% as of Jul. 2026, which is 93% above its 10-year median of 4.60. GuruFocus rates ANIX with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 1,157 Biotechnology companies, Anixa Biosciences ranks worse than 58.95% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 8.90% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 5.80% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 0.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Anixa Biosciences was 43.20% per year. The lowest was -73.10% per year. And the median was 4.60% per year.
Anixa Biosciences (NAS:ANIX) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Anixa Biosciences 3-Year EPS without NRI Growth Rate Related Terms
ANIX vs GNLX, PMN, NTHI: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Anixa Biosciences's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anixa Biosciences 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anixa Biosciences's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Anixa Biosciences's 3-Year EPS without NRI Growth Rate falls into.
Anixa Biosciences 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 8.90% mean?
Anixa Biosciences (ANIX) has a 3-Year EPS without NRI Growth Rate of 8.90% as of Jul. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Anixa Biosciences and its competitors. This is 93% above median its historical median of 4.60. According to the industry distribution chart, Anixa Biosciences ranks #682 out of 1157 companies in the Biotechnology industry, placing it in the top 58.9%.
Is Anixa Biosciences' 3-Year EPS without NRI Growth Rate too high?
Anixa Biosciences' current 3-Year EPS without NRI Growth Rate of 8.90% is 93% above median its 10-year median of 4.60. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 15.90. Anixa Biosciences' value of 8.90% is 44% below this industry median. Based on the distribution chart, Anixa Biosciences ranks #682 out of 1157 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Anixa Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' 3-Year EPS without NRI Growth Rate compare to GNLX and PMN?
According to the Biotechnology industry distribution chart, Anixa Biosciences ranks #682 out of 1157 companies for 3-Year EPS without NRI Growth Rate. This places Anixa Biosciences in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 15.90. Anixa Biosciences' value of 8.90% is 44% below this benchmark. While the company's 10-year median is 4.60 vs. the industry median of 15.90, Anixa Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 15.90, based on 1,157 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anixa Biosciences's current 3-Year EPS without NRI Growth Rate of 8.90% is 44% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Anixa Biosciences and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 15.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anixa Biosciences's current 3-Year EPS without NRI Growth Rate is 8.90%, which is 93% above median its own 10-year median of 4.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (ANIX) has a current 3-Year EPS without NRI Growth Rate of 8.90%. The current 3-Year EPS without NRI Growth Rate is 8.90%, which is 93% above median its 10-year median of 4.60 and 44% below the Biotechnology industry median of 15.90. Anixa Biosciences' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Anixa Biosciences (ANIX), the current 3-Year EPS without NRI Growth Rate is 8.90% as of Jul. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
31GF Score
Get the complete analysis for ANIX
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANIX has been successfully added to your 
